Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study

被引：0
|
作者：
B. Wolnik
A. Hryniewiecki
D. Pisarczyk-Wiza
T. Szczepanik
T. Klupa
机构：
[1] Medical University of Gdańsk,Department of Hypertension and Diabetology
[2] Sanofi-Aventis Poland,Diabetes Division
[3] Medical University of Poznan,Department of Internal Diseases and Diabetology
[4] Starkiewicz Hospital,Zaglebie Oncology Center
[5] Jagiellonian University Medical College,Department of Metabolic Diseases
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Type 2 diabetes; Elderly; Hypoglycemia; Insulin; NPH; Glargine 300;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 310
页数：9
相关论文
共 50 条
  • [31] Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis
    Sugiyama, Kazutoshi
    Meguro, Shu
    Saisho, Yoshifumi
    Irie, Junichiro
    Tanaka, Masami
    Itoh, Hiroshi
    HELIYON, 2019, 5 (02)
  • [32] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [33] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
  • [34] HEALTH ECONOMIC EVALUATIONS COMPARING THE BASAL INSULIN ANALOGUE GLARGINE (GLA) WITH NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN IN INTENSIFIED INSULIN THERAPY (ICT) IN PATIENTS WITH TYPE I DIABETES: A SYSTEMATIC REVIEW
    Hagenmeyer, E. G.
    Koltermann, K. C.
    Schaedlich, P. K.
    Haeussler, B.
    VALUE IN HEALTH, 2010, 13 (07) : A294 - A294
  • [35] Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis
    Landgraf, Wolfgang
    Owens, David R.
    Frier, Brian M.
    Bolli, Geremia B.
    DIABETES THERAPY, 2024, 15 (08) : 1769 - 1784
  • [36] Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety
    Seufert, Jochen
    Wiesli, Peter
    Fritsche, Andreas
    Anderten, Helmut
    Pegelow, Katrin
    Pscherer, Stefan
    Pfohl, Martin
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 72 - 81
  • [37] Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
    Morales, Cristobal
    de Luis, Daniel
    Ramirez de Arellano, Antonio
    Giovanna Ferrario, Maria
    Lizan, Luis
    DIABETES THERAPY, 2015, 6 (04) : 593 - 610
  • [38] Comment on "a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes"
    Freemantle, Nick
    Jourdan, Sophie
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1758 - 1759
  • [39] Cost-effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Portugal
    Cardoso, Cristina
    Ramirez de Arellano, Antonio
    Prades, Miriam
    Lizan, Luis
    JOURNAL OF DIABETES & METABOLISM, 2016, 7 (03)
  • [40] Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
    Cristóbal Morales
    Daniel de Luis
    Antonio Ramírez de Arellano
    Maria Giovanna Ferrario
    Luis Lizán
    Diabetes Therapy, 2015, 6 : 593 - 610
12345